Soluble urokinase receptor (suPAR) predicts microalbuminuria in patients at risk for type 2 diabetes mellitus

Scientific Reports

Volumn 7, Issue , 2017, Pages

  Guthoff, Martina ^a,b   Wagner, Robert ^a,b   Randrianarisoa, Elko ^a,b   Hatziagelaki, Erifili ^c   Peter, Andreas ^a,b   Häring, Hans Ulrich ^a,b   Fritsche, Andreas ^a,b   Heyne, Nils ^a,b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b GERMAN CENTER FOR DIABETES RESEARCH DZD   (Germany)

^c UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

UROKINASE RECEPTOR;

ADULT; AGED; ALBUMINURIA; BIOASSAY; BLOOD; COHORT ANALYSIS; COMPLICATION; FEMALE; HUMAN; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; SOLUBILITY;

ADULT; AGED; ALBUMINURIA; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; ENDPOINT DETERMINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; RISK FACTORS; SOLUBILITY;

EID: 85009787674     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep40627     Document Type: Article

References (30)

1. International Diabetes Federation. IDF Diabetes Atlas 7th edition. http://www.diabetesatlas.org (Date of access: 18.10.2016) (2015).
2. United States Renal Data System. Annual Data Report 2015. https://www.usrds.org/2015/view/Default.aspx (Date of access: 18.10.2016) (2015).
3. ERA-EDTA Registry, Annual Report 2014. https://www.era-edta-reg.org/files/annualreports/pdf/AnnRep2014.pdf (Date of access: 18.10.2016) (2016).
4. Gross, J. L. et al. Diabetic nephropathy: Diagnosis, prevention, and treatment. Diabetes Care 28, 164-176 (2005).
5. Sacks, D. B. et al. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Diabetes Care 34, e61-99 (2011).
6. Murussi, M., Baglio, P., Gross, J. L. & Silveiro, S. P. Risk factors for microalbuminuria and macroalbuminuria in type 2 diabetic patients: A 9-year follow-up study. Diabetes Care 25, 1101-1103 (2002).
7. Predictors of the development of microalbuminuria in patients with Type 1 diabetes mellitus: A seven-year prospective study. The Microalbuminuria Collaborative Study Group. Diabet. Med. 16, 918-925 (1999).
8. Thunø, M., Macho, B. & Eugen-Olsen, J. suPAR: The molecular crystal ball. Dis. Markers 27, 157-172 (2009).
9. Wei, C. et al. Modification of kidney barrier function by the urokinase receptor. Nat. Med. 14, 55-63 (2008).
10. Mizukami, I. F., Faulkner, N. E., Gyetko, M. R., Sitrin, R. G. & Todd, R. F. Enzyme-linked immunoabsorbent assay detection of a soluble form of urokinase plasminogen activator receptor in vivo. Blood 86, 203-211 (1995).
11. Wei, C. et al. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat. Med. 17, 952-960 (2011).
12. Montuori, N., Visconte, V., Rossi, G. & Ragno, P. Soluble and cleaved forms of the urokinase-receptor: Degradation products or active molecules Thromb. Haemost. 93, 192-198 (2005).
13. Hayek, S. S. et al. Soluble Urokinase Receptor and Chronic Kidney Disease. N. Engl. J. Med. 373, 1916-1925 (2015).
14. Haugaard, S. B. et al. The immune marker soluble urokinase plasminogen activator receptor is associated with new-onset diabetes in non-smoking women and men. Diabet. Med. 29, 479-487 (2012).
15. Heraclides, A. et al. The pro-inflammatory biomarker soluble urokinase plasminogen activator receptor (suPAR) is associated with incident type 2 diabetes among overweight but not obese individuals with impaired glucose regulation: Effect modification by smoking and body weight status. Diabetologia 56, 1542-1546 (2013).
16. Theilade, S. et al. Soluble urokinase plasminogen activator receptor levels are elevated and associated with complications in patients with type 1 diabetes. J. Intern. Med. 277, 362-371 (2015).
17. Mogensen, C. E. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N. Engl. J. Med. 310, 356-360 (1984).
18. Imai, E. et al. Reduction and residual proteinuria are therapeutic targets in type 2 diabetes with overt nephropathy: A post hoc analysis (ORIENT-proteinuria). Nephrol. Dial. Transplant. 28, 2526-2534 (2013).
19. Staeck, O. et al. Recurrent Primary Focal Segmental Glomerulosclerosis Managed With Intensified Plasma Exchange and Concomitant Monitoring of Soluble Urokinase-Type Plasminogen Activator Receptor-Mediated Podocyte β 3-integrin Activation. Transplantation 99, 2593-2597 (2015).
20. Maile, L. A. et al. Blocking a Vβ 3 integrin ligand occupancy inhibits the progression of albuminuria in diabetic rats. J. Diabetes Res. 2014, 421827 (2014).
21. Yoo, T.-H. et al. Sphingomyelinase-like phosphodiesterase 3b expression levels determine podocyte injury phenotypes in glomerular disease. J. Am. Soc. Nephrol. 26, 133-147 (2015).
22. Wu, C.-Z. et al. Urokinase plasminogen activator receptor and its soluble form in common biopsy-proven kidney diseases and in staging of diabetic nephropathy. Clin. Biochem. 48, 1324-1329 (2015).
23. Meijers, B. et al. The soluble urokinase receptor is not a clinical marker for focal segmental glomerulosclerosis. Kidney Int. 85, 636-640 (2014).
24. Wada, T. et al. A multicenter cross-sectional study of circulating soluble urokinase receptor in Japanese patients with glomerular disease. Kidney Int. 85, 641-648 (2014).
25. Singleton, J. R., Smith, A. G., Russell, J. W. & Feldman, E. L. Microvascular complications of impaired glucose tolerance. Diabetes 52, 2867-2873 (2003).
26. Mykkänen, L. et al. Microalbuminuria is associated with insulin resistance in nondiabetic subjects: The insulin resistance atherosclerosis study. Diabetes 47, 793-800 (1998).
27. Hidmark, A. et al. A new paradigm to understand and treat diabetic neuropathy. Exp. Clin. Endocrinol. Diabetes 122, 201-207 (2014).
28. Humpert, P. M. et al. Soluble RAGE but not endogenous secretory RAGE is associated with albuminuria in patients with type 2 diabetes. Cardiovasc. Diabetol. 6, 9 (2007).
29. Levey, A. S. et al. A new equation to estimate glomerular filtration rate. Ann. Intern. Med. 150, 604-612 (2009).
30. Schemper, M., Wakounig, S. & Heinze, G. The estimation of average hazard ratios by weighted Cox regression. Stat. Med. 28, 2473-2489 (2009).